Osteoporosis is a major public health problem in our aging population. Fragility fractures cause pain, lack of functional independence, and increased mortality. New therapeutic strategies are sorely needed to boost bone formation and cure osteoporosis. In the Wein laboratory, we study the signaling cascades and gene networks that bone cells use during normal skeletal development and remodeling. We aim to understand and exploit normal bone regenerative pathways in order to develop new treatments for osteoporosis, fracture repair, and other skeletal diseases. To this end, novel drug targets have been identified by detailed examination of the signaling pathways used by mechanical loading and parathyroid hormone to normally stimulate bone formation. We use a collaborative approach to bring cutting-edge technologies to solve clinically-important problems in musculoskeletal biology and mineral metabolism.

Biosketch
Marc Wein is an Assistant Professor of Medicine at Harvard Medical School and an Associate Member of the Broad Institute. Marc received his B.S. and M.S. from Yale University, M.D. and Ph.D. from Harvard Medical School, and was trained in Internal Medicine and Endocrinology at Massachusetts General Hospital where he currently runs his research laboratory and clinical practice. He has received research funding and awards from the NIH, American Society of Clinical Investigation, Harrington Discovery Institute, Endocrine Society, Stepping Strong Center for Trauma Innovation, American Society of Bone and Mineral Research, and the Smith Family Foundation.